云南药品安全连续多年零重特大事故

Core Insights - The pharmaceutical safety situation in Yunnan Province is stable and improving, with zero major accidents over several years, and the biopharmaceutical industry revenue expected to exceed 320 billion yuan in 2024, reaching 323.17 billion yuan [1][2] Group 1: Pharmaceutical Safety - The drug inspection pass rate in Yunnan reached 99.53%, surpassing the national average of 99.4%, indicating a continuous improvement in drug safety [1] - The provincial drug regulatory authority has implemented a comprehensive regulatory mechanism, ensuring all drug operating and usage units are under supervision, with full coverage of high-risk drugs and vaccine production enterprises [1] - During the "14th Five-Year Plan" period, the number of administrative penalty cases related to "two products and one device" (drugs, cosmetics, and medical devices) increased more than twofold, with the value involved rising by 15.7 times, effectively purifying the market environment [1] Group 2: Industry Development - Yunnan's drug regulatory department has actively extended its role as a "service provider" to promote industry development, publishing 414 provincial standards for traditional Chinese medicine formula granules, with 48.6% of national reference medicinal materials coming from ethnic medicine [2] - The province has pioneered a "base evaluation + extended inspection" mechanism, extending quality management of traditional Chinese medicine from processing to the planting source, leading to the highest import volume and value of traditional Chinese medicine in the country in 2024 [2] - The digital transformation is key to enhancing regulatory efficiency, with the establishment of the "Drug Supervision Eye" platform utilizing big data and cloud computing for intelligent monitoring across the entire drug production, circulation, and usage chain [2] Group 3: Regulatory Achievements - Yunnan is the only province fully participating in the World Health Organization's vaccine national regulatory system assessment and international drug inspection cooperation program, providing significant support for the country's successful evaluation by the WHO [2] - The provincial drug regulatory authority has created a nationally recognized civilized unit and formed a large-scale, professional inspector team, ranking among the top in the southwest region [2] - Yunnan will continue to balance safety and development, promoting high-quality growth in the biopharmaceutical industry to ensure public medication safety and contribute to the health of the province [2]